ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0820

Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study

Diala Alawneh1, Moustafa Younis2, Bashar Alzghoul2, Christian Ascoli1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Divya Patel2, Israel Rubinstein1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

Meeting: ACR Convergence 2022

Keywords: Miscellaneous Rheumatic and Inflammatory Diseases, Patient reported outcomes, population studies, registry

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate therapy has been published. Accordingly, we sought to determine therapeutic practices and outcomes of patients with chronic sarcoidosis arthropathy in the United States (US) based on a national registry questionnaire.

Methods: We conducted a retrospective review of 3,835 respondents to the Foundation for Sarcoidosis Research – Sarcoidosis Advanced Registry for Cures Questionnaire (FSR-SARC). This US-based registry comprises of patient surveys completed between June 2014 and August 2019. Data is presented as means ± SD, odds ratio (OR) and confidence intervals (IR) where appropriate. Univariate data analyses were performed as indicated. P< 0.05 was considered statistically significant.

Results: A total of 773 (20%) patients with chronic sarcoidosis arthropathy with a mean (± SD) age of 42 (±12) years were identified; 634 (82%) were female, 578 (75%) Caucasian, and 161 (21%) African American. Among these, 713 (92%) had multiorgan involvement (defined as >=3 organs). Patients with chronic sarcoidosis arthropathy were 19 times more likely to have multiorgan involvement in comparison to those without (OR= 19; 95% CI: 14-25; p< 0.0001). These patients were more likely to be disabled (OR= 2.4; 95% CI: 2.0-2.8; p< 0.0001) and require mobility devices (OR= 2.5; 95% CI: 2.0-3.1; p< 0.0001). Patients with chronic sarcoidosis arthropathy had the following associated chronic disorders: 71 (11%) had Lofgren syndrome, 192 (25%) had fibromyalgia, 278 (36%) had chronic fatigue syndrome and 281 (37%) had chronic pain syndrome. Patients with chronic sarcoidosis arthropathy were 3.5 times more likely to have fibromyalgia (OR=3.5; 95% CI: 2.8-4.5; p< 0.0001).

A total of 690 (99%) patients received the following therapies during the course of their disease; 657 (85%) corticosteroids, 484 (80%) cytotoxic medications, and 186 (36%) TNF-α inhibitors. Patients with sarcoidosis arthropathy were actively on the following treatments: 505 (65%) acetaminophen/NSAIDS, 330 (43%) narcotics, 291 (38%) COX-2 inhibitors/ gabapentin/ pregabalin/ tramadol, 116 (15%) hydroxychloroquine, 34 (4%) corticosteroids, 153 (20%) methotrexate, 40 (5%) azathioprine, 25 (3%) leflunomide, 34 (4%) mycophenolate mofetil, 62 (8%) infliximab, 23 (3%) adalimumab, 7 (1%) rituximab, 4 (0.5%) cyclophosphamide, 16 (2%) IVIG, and 202 (26%) physical therapy.

Patients with chronic sarcoidosis arthropathy were more likely to be treated with corticosteroids, hydroxychloroquine, cytotoxic medications, and TNF-α inhibitors than those without chronic arthropathy as shown in figure 1 (all odds were statistically significant with p< 0.0001) .

Conclusion: The prevalence of chronic sarcoidosis arthropathy in this US cohort was similar to that reported in the literature. This condition is disabling and limits patient’s activity of daily living. In addition, these patients are more likely to have multiorgan involvement. Corticosteroids, NSAIDs and hydroxychloroquine were the most commonly prescribed therapies.

Supporting image 1

Figure 1: Odds of different therapies when comparing patients with sarcoidosis arthropathy vs those without.


Disclosures: D. Alawneh, None; M. Younis, None; B. Alzghoul, None; C. Ascoli, None; T. Shivas, None; M. McGowan, None; K. Alawneh, None; D. Patel, None; I. Rubinstein, None; N. Sweiss, None.

To cite this abstract in AMA style:

Alawneh D, Younis M, Alzghoul B, Ascoli C, Shivas T, McGowan M, Alawneh K, Patel D, Rubinstein I, Sweiss N. Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/therapeutic-practices-and-outcomes-of-chronic-sarcoidosis-arthropathy-in-the-united-states-a-nationwide-registry-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-practices-and-outcomes-of-chronic-sarcoidosis-arthropathy-in-the-united-states-a-nationwide-registry-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology